Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies

Overview

Journal Saudi Dent J

Specialty Dentistry

Date 2022 Aug 8

PMID 35935720

Authors

Raed AlRowis

Abdulmalik Aldawood

Mohammed Alotaibi

Essam Alnasser

Ibrahim AlSaif

Abdullah Aljaber

Zuhair Natto

Affiliations

Soon will be listed here.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a major problem that can occur in people taking certain medications such bisphosphonates and denosumab. It can be used to treat osteoporosis or cancer. Bisphosphonate exposure, dental diseases and procedures, age, sex, anatomical factors, medical issues, and hereditary factors are all variables that enhance the risk of MRONJ. Even though MRONJ and antiresorptive medications have a close association, the pathophysiology of MRONJ is unknown. Careful dental preparation and oral hygiene instructions significantly minimize the risk of osteonecrosis of the jaw (ONJ). It is ideal to start antiresorptive treatment after the completion of required dental treatment; it is not contraindicated and carries low risk in patients who are on oral antiresorptive medications for less than three years. Drug holidays are one proposed solution to address MRONJ. However, there is still inadequate evidence to support their effectiveness. The objectives of this literature review are to recognize the main diagnostic principles and risk factors and to review the pathophysiology, protective procedures and treatment modalities related to MRONJ. The following topics are covered in the review: epidemiology, diagnostic criteria, risk factors, pathogenesis and mechanism, MRONJ staging and symptoms, clinical and radiographic findings, treatment strategies, prevention and drug holiday.

Citing Articles

The Microbiological Background of Medication-Related Osteonecrosis of the Jaw (MRONJ): Clinical Evidence Based on Traditional Culture and Molecular Biological Detection Methods.

Kover Z, Gajdacs M, Polgar B, Szabo D, Urban E Antibiotics (Basel). 2025; 14(2).

PMID: 40001446 PMC: 11851722. DOI: 10.3390/antibiotics14020203.

Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol.

Slowik L, Toton E, Nowak A, Wysocka-Slowik A, Okla M, Slebioda Z J Clin Med. 2025; 14(3).

PMID: 39941644 PMC: 11818125. DOI: 10.3390/jcm14030974.

Comparison of the Effects of Four Laser Wavelengths on Medication-Related Osteonecrosis of the Jaw (MRONJ) in a Murine Model: An Photobiomodulation Study.

Ayhan M, Gedik B, Kalelioglu E, Kundakcioglu A, Kucukgergin C, Turgut C Int J Med Sci. 2024; 21(15):2959-2973.

PMID: 39628679 PMC: 11610323. DOI: 10.7150/ijms.93224.

Effectiveness of Local Use of Green Propolis-Loaded Lipid Nanoparticles as Adjuvant Therapy to Scaling and Root Planing in the Management of Periodontitis in Rats Treated with Zoledronate.

Silveira G, Ganzaroli V, Toro L, Lopes-Pereira E, Costa L, Mello-Neto J Int J Mol Sci. 2024; 25(22).

PMID: 39596508 PMC: 11595208. DOI: 10.3390/ijms252212443.

Oral and Gingival Crevicular Fluid Biomarkers for Jawbone Turnover Diseases: A Scoping Review.

Fadli N, Abdul Rahman M, Karsani S, Ramli R Diagnostics (Basel). 2024; 14(19).

PMID: 39410587 PMC: 11475764. DOI: 10.3390/diagnostics14192184.

References

Malden N, Lopes V . An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2011; 30(2):171-82. DOI: 10.1007/s00774-011-0299-z. View

Loyson T, Van Cann T, Schoffski P, Clement P, Bechter O, Spriet I . Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg. 2017; 73(2):100-109. DOI: 10.1080/17843286.2017.1348001. View

Lerman M, Xie W, Treister N, Richardson P, Weller E, Woo S . Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013; 49(9):977-983. DOI: 10.1016/j.oraloncology.2013.05.012. View

van Cann T, Loyson T, Verbiest A, Clement P, Bechter O, Willems L . Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer. 2017; 26(3):869-878. DOI: 10.1007/s00520-017-3903-5. View

Fusco V, Santini D, Armento G, Tonini G, Campisi G . Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf. 2016; 15(7):925-35. DOI: 10.1080/14740338.2016.1177021. View

Barasch A, Cunha-Cruz J, Curro F, Hujoel P, Sung A, Vena D . Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res. 2011; 90(4):439-44. PMC: 3144129. DOI: 10.1177/0022034510397196. View

Limones A, Saez-Alcaide L, Diaz-Parreno S, Helm A, Bornstein M, Molinero-Mourelle P . Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020; 25(3):e326-e336. PMC: 7211372. DOI: 10.4317/medoral.23324. View

Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I . Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010; 122(1):181-8. DOI: 10.1007/s10549-010-0866-3. View

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

10.

Khan A, Rios L, Sandor G, Khan N, Peters E, Rahman M . Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol. 2011; 38(7):1396-402. DOI: 10.3899/jrheum.100221. View

11.

Lee S, Gong H, Kim T, Park S, Shin J, Cho S . Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea. J Bone Metab. 2015; 22(4):167-74. PMC: 4691590. DOI: 10.11005/jbm.2015.22.4.167. View

12.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

13.

Srivastava A, Nogueras Gonzalez G, Geng Y, Won A, Cabanillas M, Naing A . Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2020; 29(5):2305-2317. DOI: 10.1007/s00520-020-05882-3. View

14.

Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu M . Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-36. PMC: 2677083. DOI: 10.1359/jbmr.080205. View

15.

Hansen P, Knitschke M, Draenert F, Irle S, Neff A . Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk?. Clin Oral Investig. 2012; 17(8):1829-37. DOI: 10.1007/s00784-012-0873-3. View

16.

Kalra S, Jain V . Dental complications and management of patients on bisphosphonate therapy: A review article. J Oral Biol Craniofac Res. 2015; 3(1):25-30. PMC: 3942225. DOI: 10.1016/j.jobcr.2012.11.001. View

17.

Fortunato L, Amato M, Simeone M, Bennardo F, Barone S, Giudice A . Numb chin syndrome: A reflection of malignancy or a harbinger of MRONJ? A multicenter experience. J Stomatol Oral Maxillofac Surg. 2018; 119(5):389-394. DOI: 10.1016/j.jormas.2018.04.006. View

18.

Hallmer F, Bjarnadottir O, Gotrick B, Malmstrom P, Andersson G . Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020; 130(3):252-257. DOI: 10.1016/j.oooo.2020.04.808. View

19.

Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K . Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012; 41(11):1397-403. DOI: 10.1016/j.ijom.2012.06.020. View

20.

Ruggiero S . Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg. 2009; 67(5 Suppl):13-8. DOI: 10.1016/j.joms.2008.10.005. View